CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, has recently introduced a new range of Imaging Analysis services for the scientific community to accelerate their drug discovery and development, including the Drug Targets Imaging Analysis, the In Vivo Drug Delivery Imaging Monitoring, the Imaging Monitoring of Biomarkers in Tissues, and the Drug Toxicity Imaging Analysis.
Drug discovery is an interdisciplinary field that focuses on the in vitro, ex vivo and in vivo identification and preclinical testing of drug candidates. The drug development process itself is typically divided into two distinct yet interconnected phases, research and development. These stages follow a sequential order, with the research phase preceding the identification of candidate drugs. Once candidate drugs are selected, the development phase commences. In recent years, the integration of imaging technology has revolutionized drug research and development, significantly advancing the medical field.
In recent decades, high-resolution electron microscopy has made it possible to study the structure of drug targets, helping researchers to design synthetically relevant drug candidates. In addition, a lack of clarity about the cellular signalling pathways involved in drug action can lead to unmeasured side effects and slow down drug development. Cellular imaging can help to analyze the underlying mechanisms. Thus, molecular imaging plays an important role in drug discovery.
CD BioSciences has been developing imaging technologies for many years and boasts a team of experienced researchers specializing in imaging analysis. The company can provide clients with imaging services for drug discovery and development, including imaging of drug targets, imaging of biomarkers in tissues, imaging of toxicity and in vivo imaging of drug efficacy. These imaging analysis services can not only provide an important theoretical basis for drug discovery and development, but also reduce the associated costs and streamline the development timeline.
For example, CD BioSciences offers Drug Toxicity Imaging Analysis services throughout the drug development process, including hepatotoxicity imaging, liver fibrosis imaging, mitochondrial function imaging, cardiotoxicity imaging, and nephrotoxicity imaging. Its experienced team utilizes high-content imaging systems to analyze multiple drug toxicity parameters concurrently, generating high-quality data efficiently and cost-effectively. Unlike conventional in vitro toxicity testing with limited insights, high-content screening can simultaneously monitor and analyze multiple indicators of drug toxicity, such as cell number, survival, apoptosis, calcium ion levels, and mitochondrial membrane potential, offering a more comprehensive assessment of drug toxicity.
CD BioSciences has been engaged in the development of imaging technology for many years. The company can design personalized imaging analysis plans based on the client's needs and provide accurate and reproducible experimental data. To find out more about the new Imaging Analysis services, please visit https://www.bioimagingtech.com/imaging-analysis-for-drug-discovery-development.html.
About CD BioSciences
CD BioSciences is a biotechnology company committed to the development of imaging technology for many years. Its scientists can utilize high-content imaging, nanoparticle imaging, imaging flow cytometry, time-lapse imaging, and other techniques to image cell structure, cell migration, cell proliferation, pathogen infection mechanisms, and interactions between protein molecules.
Media Contact
Company Name: CD BioSciences
Contact Person: Michelle Moser
Email: Send Email
State: New York
Country: United States
Website: https://www.bioimagingtech.com/
